Parkinson disease (PD) is a progressive disorder characterized by dopaminergic
neurodegeneration in the brain. The development of parkinsonism is preceded by a long …

Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …

The unmet timely diagnosis requirements, that take place years after substantial neural loss
and neuroperturbations in neuropsychiatric disorders, affirm the dire need for biomarkers …

Background Development of reliable and accurate imaging biomarkers of dopaminergic cell
neurodegeneration is necessary to facilitate therapeutic drug trials in Parkinson's disease …

Previous studies have reported substantial involvement of the noradrenergic system in
Parkinson's disease. Neuromelanin-sensitive MRI sequences and PET tracers have become …

In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function,
and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition …

Parkinson's disease (PD) is a neurodegenerative synucleinopathy characterized by the
degeneration of neuromelanin (NM)-containing dopaminergic neurons and deposition of …

Disruptions to dopamine and noradrenergic neurotransmission are noted in several
neurodegenerative and psychiatric disorders. Neuromelanin-sensitive (NM)-MRI offers a …

Objective The motor severity in Parkinson disease (PD) is believed to parallel dopaminergic
terminal degeneration in the striatum, although the terminal was reported to be virtually …